Citations

Clear

9383 citation(s) found for "Thomas, PS".

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
Aurora, SK, Dodick, DW, Turkel, CC, DeGryse, RE, Silberstein, SD, Lipton, RB, Diener, HC, Brin, MF, Dashtipour, Khashayar

Mayo Clinic

Cephalalgia | March 17, 2010 | Volume: 30 | Issue: 7 | Pages: 793-803

10.1177/0333102410364676 | PMID 20647170 Get It

Objectives: This is the first of a pair of studies designed to assess efficacy, safety and tolerability of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic migraine. Methods: The Phase III REsearch Evaluating Migraine Prophylaxis Therapy 1 (PREEMPT 1) is a phase 3 study, with a 24-week, double-blind, parallel-group, placebo-controlled phase followed by a 32-week, open-label phase. Subjects were randomized (1:1) to injections every 12 weeks of onabotulinumtoxinA (155 U–195 U; n = 341) or placebo ( n = 338) (two cycles). The primary endpoint was mean change from baseline in headache episode frequency at week 24. Results: No significant between-group difference for onabotulinumtoxinA versus placebo was observed for the primary endpoint, headache episodes (−5.2 vs. −5.3; p = 0.344). Large within-group decreases from baseline were observed for all efficacy variables. Significant between-group differences for onabotulinumtoxinA were observed for the secondary endpoints, headache days ( p = .006) and migraine days ( p = 0.002). OnabotulinumtoxinA was safe and well tolerated, with few treatment-related adverse events. Few subjects discontinued due to adverse events. Conclusions: There was no between-group difference for the primary endpoint, headache episodes. However, significant reductions from baseline were observed for onabotulinumtoxinA for headache and migraine days, cumulative hours of headache on headache days and frequency of moderate/severe headache days, which in turn reduced the burden of illness in adults with disabling chronic migraine.
Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate
Seeman, Ego , Delmas, Pierre D., Hanley, David A. , Sellmeyer, Deborah E. , Cheung, Angela M. , Shane, Elizabeth , Kearns, Ann E. , Thomas, Thierry , Boyd, Steven K. , Boutroy, Stéphanie , Bogado, César E., Fan, Michelle, Zanchetta, José, Majumdar, Sharmila , Libanati, Cesar R. , Boyd, Steven K , Cheung, Angela M

Mayo Clinic

Journal of Bone and Mineral Research | March 10, 2010 | Volume: 25 | Issue: 8 | Pages: 1886-1894

10.1002/jbmr.81 | PMID 20222106 Get It

Abstract The intensity of bone remodeling is a critical determinant of the decay of cortical and trabecular microstructure after menopause. Denosumab suppresses remodeling more than alendronate, leading to greater gains in areal bone mineral density (aBMD). These greater gains may reflect differing effects of each drug on bone microarchitecture and strength. In a phase 2 double-blind pilot study, 247 postmenopausal women were randomized to denosumab (60 mg subcutaneous 6 monthly), alendronate (70 mg oral weekly), or placebo for 12 months. All received daily calcium and vitamin D. Morphologic changes were assessed using high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal radius and distal tibia and QCT at the distal radius. Denosumab decreased serum C-telopeptide more rapidly and markedly than alendronate. In the placebo arm, total, cortical, and trabecular BMD and cortical thickness decreased (−2.1% to −0.8%) at the distal radius after 12 months. Alendronate prevented the decline (−0.6% to 2.4%, p = .051 to <.001 versus placebo), whereas denosumab prevented the decline or improved these variables (0.3% to 3.4%, p < .001 versus placebo). Changes in total and cortical BMD were greater with denosumab than with alendronate (p ≤ .024). Similar changes in these parameters were observed at the tibia. The polar moment of inertia also increased more in the denosumab than alendronate or placebo groups (p < .001). Adverse events did not differ by group. These data suggest that structural decay owing to bone remodeling and progression of bone fragility may be prevented more effectively with denosumab. © 2010 American Society for Bone and Mineral Research
Hypersensitivity Vasculitis with Leukocytoclastic Vasculitis Associated with Alpha-1-Proteinase Inhibitor
Mwirigi, Nicola W., Thomas, Charles F.

Mayo Clinic

Case Reports in Medicine | February 24, 2010 | Volume: 2009 | Issue: No issue available | Pages: 1-6

10.1155/2009/941258 | PMID 20204065 Get It

Prolastin is a commercially available form of alpha-1-antitrypsin (AAT) that is derived from pooled human plasma and used for treatment of severe alpha-1-antitrypsin deficiency (AATD). We describe a patient with AATD who developed presumed hypersensitivity vasculitis (HV) following a Prolastin infusion. Hypersensitivity vasculitis (HV), or cutaneous vasculitis, is characterized by inflammation of the small vessels of the skin with resultant ischemia to the distally supplied areas. To our knowledge, this is the first reported case of presumed hypersensitivity vasculitis following Prolastin infusion.
Protein Kinase Cι Is Required for Pancreatic Cancer Cell Transformed Growth and Tumorigenesis
Scotti, Michele L., Bamlet, William R. , Smyrk, Thomas C. , Fields, Alan P. , Murray, Nicole R. , Bamlet, William R

Mayo Clinic

Cancer Research | February 23, 2010 | Volume: 70 | Issue: 5 | Pages: 2064-2074

10.1158/0008-5472.can-09-2684 | PMID 20179210 Get It

Abstract Pancreatic cancer is the fourth leading cause of cancer deaths in the United States, with an overall 5-year survival rate of <5%. Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is highly resistant to conventional chemotherapies, underscoring the critical need for new molecular targets for pancreatic cancer chemotherapy. The KRAS proto-oncogene is mutated in >90% of PDAC. Protein kinase Cι (PKCι) is required for the oncogenic Ras–mediated transformed growth of lung cancer and intestinal epithelial cells. However, little is known about the role of PKCι in pancreatic cancer. In this study, we evaluated the expression of PKCι in human pancreatic cancer and the requirement for PKCι for the transformed growth and tumorigenicity of PDAC cells. We find that PKCι is significantly overexpressed in human pancreatic cancer, and high PKCι expression correlates with poor patient survival. Inhibition of PKCι expression blocks PDAC cell transformed growth in vitro and tumorigenicity in vivo. Inhibition of PKCι expression in pancreatic tumors also significantly reduces tumor angiogenesis and metastasis. Analysis of downstream PKCι effectors implicates the Rac1-MEK/ERK1/2 signaling axis in PKCι-mediated transformed growth and cellular invasion. Taken together, our data show a required role for PKCι in the transformed growth of pancreatic cancer cells and reveal a novel role for PKCι in pancreatic cancer cell metastasis and angiogenesis in vivo. Our results strongly indicate that PKCι will be an effective target for pancreatic cancer therapy. Cancer Res; 70(5); 2064–74
Role of BMI in the Association of theTCF7L2rs7903146 Variant with Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study
Kucharska‐Newton, Anna , Monda, Keri L., Bielinski, Suzette J. , Boerwinkle, Eric , Rosamond, Wayne D. , Pankow, James S. , Köttgen, Anna , Heiss, Gerardo , Rea, Thomas D. , North, Kari E. , Bielinski, Suzette , Pankow, James S , Kucharska-Newton, Anna M

Mayo Clinic

Journal of Obesity | February 22, 2010 | Volume: 2010 | Issue: No issue available | Pages: 1-5

10.1155/2010/651903 | PMID 20798759 Get It

We examined the association of variation in the type 2 diabetes risk-conferringTCF7L2gene with the risk of incident coronary heart disease (CHD) among the lean, overweight, and obese members of the Atherosclerosis Risk in Communities (ARIC) Study cohort. Cox proportional hazard regression analyses were performed using a general model, with the major homozygote as the reference category. For 9,865 whites, a significant increase in the risk of CHD was seen only among lean (BMI<25 kg/m2) individuals homozygous for theTallele of theTCF7L2rs7903146 gene risk variant (hazard ratio 1.42; 95% CI 1.03,1.97;P=.01). No association was found among 3,631 blacks, regardless of BMI status. An attenuated hazard ratio was observed among the nondiabetic ARIC cohort members. This study suggests that body mass modifies the association of theTCF7L2rs7903146 T allele with CHD risk.
MRI After Technically Successful Renal Cryoablation: Early Contrast Enhancement as a Common Finding
Porter, Christopher A. , Woodrum, David A. , Callstrom, Matthew R. , Schmit, Grant D. , Misra, Sanjay , Charboneau, J. William, Atwell, Thomas D. , Misra, Sanjay

Mayo Clinic

American Journal of Roentgenology | February 19, 2010 | Volume: 194 | Issue: 3 | Pages: 790-793

10.2214/ajr.09.2518 | PMID 20173161 Get It

Hydrodisplacement in the Percutaneous Cryoablation of 50 Renal Tumors
Bodily, Kale D., Atwell, Thomas D. , Mandrekar, Jayawant N. , Farrell, Michael A., Callstrom, Matthew R. , Schmit, Grant D. , Charboneau, J. William

Mayo Clinic

American Journal of Roentgenology | February 19, 2010 | Volume: 194 | Issue: 3 | Pages: 779-783

10.2214/ajr.08.1570 | PMID 20173159 Get It

Incidence of Bleeding After 15,181 Percutaneous Biopsies and the Role of Aspirin
Atwell, Thomas D. , Smith, R. L., Hesley, Gina K. , Callstrom, Matthew R. , Schleck, Cathy D. , Harmsen, William S. , Charboneau, J. William, Welch, Timothy J.

Mayo Clinic

American Journal of Roentgenology | February 19, 2010 | Volume: 194 | Issue: 3 | Pages: 784-789

10.2214/ajr.08.2122 | PMID 20173160 Get It

Changes in Left and Right Ventricular Mechanics During the Mueller Maneuver in Healthy Adults
Koshino, Yuki, Villarraga, Hector R. , Orban, Marek , Pressman, Gregg S. , Leinveber, Pavel , Saleh, Haydar K., Konečný, Tomáš , Kára, Tomáš, Bruce, Charles J. , Somers, Virend K. , López-Jiménez, Francisco

Mayo Clinic

Circulation: Cardiovascular Imaging | February 17, 2010 | Volume: 3 | Issue: 3 | Pages: 282-289

10.1161/circimaging.109.901561 | PMID 20160141 Get It

Background— Obstructive sleep apnea is highly prevalent in patients with cardiovascular disease and has detrimental effects on systolic and diastolic function of the ventricles. In this research, the changes in strain (S) and strain rate (SR) during the performance of the Mueller maneuver (MM) in an effort to better understand how negative intrathoracic pressures affect ventricular mechanics. Methods and Results— The MM was performed to maintain a target intrathoracic pressure of −40 mm Hg. Echocardiography was used to measure various parameters of cardiac structure and function. Myocardial deformation measurements were performed using tissue speckle tracking. Twenty-four healthy subjects (9 women; mean age, 30�6 years) were studied. Global left ventricular longitudinal S in systole and SR in early filling were significantly decreased during the MM (S: baseline, −17.0�1.6%; MM, −14.5�2.2%; P <0.0001, SR: baseline, 1.09�0.20 s −1 ; MM, 0.92�0.21 s −1 ; P =0.01). Global right ventricular longitudinal S was also significantly decreased during the MM (baseline, −22.0�3.1%; MM, −17.2�2.5%; P <0.0001), as was global right ventricular longitudinal systolic SR (baseline, −1.34�0.35 s −1 ; MM, −1.02�0.21 s −1 ; P =0.0006). Conclusions— Left ventricular and right ventricular longitudinal deformation are significantly reduced during the MM. These results suggest that negative intrathoracic pressure during apnea may contribute to changes in myocardial mechanics. These results could help explain the observed changes in left ventricular and right ventricular mechanics in patients with obstructive sleep apnea.
Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia
LaPlant, Betsy, Camoriano, John , Hayman, Suzanne R. , Lacy, Martha Q. , Chuma, Stacey, Harris, Brianna , Leduc, Renee, Rourke, Meghan, Ansell, Stephen M. , Dispenzieri, Angela , Bergsagel, Leif, Reeder, Craig B. , Richardson, Paul G. , Bergsagel, P. Leif , Borchin, Renée , Ghobrial, Irene M. , Gertz, Morie A. , DeAngelo, Daniel J. , Anderson, Kenneth C. , Richardson, Paul Gerard Guy , Treon, Steven P. , Witzig, Thomas E. , Bergsagel, P. Leif , Dispenzieri, Angela , Harris, Brianna N

Mayo Clinic

Journal of Clinical Oncology | February 8, 2010 | Volume: 28 | Issue: 8 | Pages: 1408-1414

10.1200/jco.2009.24.0994 | PMID 20142598 Get It

Purpose The phosphatidylinositol 3-kinase/mammalian target of rapamycin (mTOR) signal transduction pathway controls cell proliferation and survival. Everolimus is an oral agent targeting raptor mTOR (mTORC1). The trial's goal was to determine the antitumor activity and safety of single-agent everolimus in patients with relapsed/refractory Waldenström macroglobulinemia (WM). Patients and Methods Eligible patients had measurable disease (immunoglobulin M monoclonal protein > 1,000 mg/dL with > 10% marrow involvement or nodal masses > 2 cm), a platelet count more than 75,000 × 10 6 /L, a neutrophil count more than 1,000 × 10 6 /L, and a creatinine and bilirubin less than 2 × the laboratory upper limit of normal. Patients received everolimus 10 mg orally daily and were evaluated monthly. Tumor response was assessed after cycles 2 and 6 and then every three cycles until progression. Results Fifty patients were treated. The median age was 63 years (range, 43 to 85 years). The overall response rate (complete response plus partial remission [PR] plus minimal response [MR]) was 70% (95% CI, 55% to 82%), with a PR of 42% and 28% MR. The median duration of response and median progression-free survival (PFS) have not been reached. The estimated PFS at 6 and 12 months is 75% (95% CI, 64% to 89%) and 62% (95% CI, 48% to 80%), respectively. Grade 3 or higher related toxicities were observed in 56% of patients. The most common were hematologic toxicities with cytopenias. Pulmonary toxicity occurred in 10% of patients. Dose reductions due to toxicity occurred in 52% of patients. Conclusion Everolimus has high single-agent activity with an overall response rate of 70% and manageable toxicity in patients with relapsed WM and offers a potential new therapeutic strategy for this patient group.